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EDITORIAL
A dynamic interplay between monocyte chemoattractant
protein-1 and heme oxygenase-1: Implications in renal injury
Emerging evidence during the last decade suggests that
there is an intricate interdependent relationship between
heme oxygenase-1 (HO-1) and chemokine monocyte
chemoattractant protein-1 (MCP-1) in various inflamma-
tory disease processes of the kidney while undergoing cel-
lular stress and consequential apoptosis [1]. The evidence
of such lively interactions between HO-1 and MCP-1 has
been described both in tubular as well as glomerular in-
jury, but it may be more so evident in the tubulointerstitial
compartment of the kidney [2]. The article by Pittock et
al in this issue of Kidney International serves as an exem-
plary subject matter where authors convincingly demon-
strate the modulation of MCP-1 by HO-1 that consequen-
tially affects the activity of ubiquitous transcription fac-
tor, NFjB, both under stressed and nonstressed states in
HO-1–deficient (HO-1−/−) mice [3].
HO-1 is a 33 kD microsomal protein that is induced
as an adaptive response to a wide variety of injurious
stimuli, including heme, low/high oxygen tension, endo-
toxin, heat shock, and heavy metals [4, 5]. In addition,
HO-1 is induced by various cytokines, growth factors,
and oxidized LDL. The induced HO-1 serves as a rate-
limiting step in heme degradation, resulting in the forma-
tion of CO, iron, and biliverdin. The latter is converted
into bilirubin by biliverdin reductase. In contrast to heme,
its enzymatic degradation products have important bio-
logical effects, including antioxidant, anti-inflammatory,
and cytoprotective functions, suggesting that the induc-
tion of HO-1 serves as a shielding effect, implicated in
numerous clinically relevant disease states, such as trans-
plant rejection, hypertension, atherosclerosis, acute lung
and renal injury, endotoxic shock, and others [4, 5]. On
the other hand, MCP-1contributes in the progression of
these disease processes by directional trafficking of the
mononuclear cells at the site of cellular injury [6]. MCP-
1 is a low-molecular cytokine and belongs to the sub-
family of C-C chemokines, also known as b-cytokines. It
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activates monocytes and modulates hematopoiesis, an-
giogenesis, atherogenesis and thereby, various inflamma-
tory processes. Its receptor, CCR2, conceivably is ex-
pressed or induced to express in all the renal cell types,
suggesting that the biology of MCP-1 may be relevant
in both glomerular and tubulointerstitial injuries. More-
over, the local production of MCP-1, in particular by the
tubular cells, would indicate that it may not be only in-
volved in the initiation of the injury but may also fur-
ther contribute in the progression of tubulointerstitial
diseases. For instance, MCP-1 can trigger a cascade of
various MAP kinases, thus activating transcription fac-
tors like NFjB and activating protein-1 (AP-1), which
would then induce expression of interleukin-6 (IL-6) and
intracellular adhesion molecule-1 (ICAM-1). The ICAM
induction would facilitate further recruitment of mono-
cytes, and thereby, perpetuation of the tubular injury and
interstitial fibrosis. The latter in part would be related to
increased transcription of collagen genes modulated by
NFjB and other cytokines (e.g., TGF-b) [7]. These com-
plex interactions in the pathogenesis of tubulointerstitial
injury are highlighted in an accompanying article of this
issue, and are also reflected in the preceding elegant work
carried out by Nath et al during the last decade [4, 8].
In a previous study, they postulated HO-1 exerts its cy-
toprotective and anti-inflammatory effect by suppressing
the expression of MCP-1 [8]. Given the relevance of
MCP-1 in renal injury related to inflammatory, ischemic,
or toxic assaults and the protection conferred by HO-1
in ischemic-reperfusion injury to the kidney, Pittock et al
utilized HO-1−/− mice in the current investigation [3] to
address the following: (1) what is the nature of interplay
between these two molecules with opposing effects?; (2)
what are the systemic effects if any?; (3) is there any in-
duction of profibrogenic cytokines that is influenced by
various transcription factors?; and, most importantly, (4)
what is the status of these molecules under unstressed
physiologic states?
Overall, relative to the control wild-type HO-1+/+
mice, an accentuated increased MCP-1 expression was
observed in all the three forms of stresses (i.e., is-
chemia/reperfusion injury, hemoglobin administration,
and aging in HO-1−/− mice) [3]. The most dramatic
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effects were seen in the ischemia/reperfusion injury
model, in which marked increased MCP-1 expression was
seen along with increased activity of caspase-3, an enzyme
involved in the induction of apoptosis in a wide variety
of eukaryotic cells, and it was associated with increased
mortality. The increased mortality in this model was per-
haps related to the systemic up-regulation of MCP-1 with
consequential injury to distant organs, such as lungs and
heart. Conceivably, the local tissue deficiency of HO-1 in
other organ systems may have contributed to increased
mortality in these mice. Such distant cytokine-mediated
effects on the heart and lungs have been well described
in ischemia/reperfusion animal models, and are also ob-
served in patients with acute renal failure [9, 10]. The
relevance of HO-1 in chronic injury was elucidated in
the aging HO-1−/− mice, where increased transcription of
collagen genes, profibrogenic cytokine, TGF-b , and pro-
liferative forms of glomerulonephritis and tubulointersti-
tial fibrosis were observed. This would imply that HO-1
and MCP-1 have sustained long-lasting dynamic interplay
that modulates acute as well as chronic injury. The most
intriguing observation made by Nath et al in the accom-
panying article relates to the MCP-1 regulation under
nonstressed state [3]. In the hemoglobin-induced toxic
chemical injury model, they observed that even intro-
duction of a syringe needle into the vein with or without
any administration of physiologic saline led to a 5-fold
increased expression of MCP-1 mRNA in HO-1−/− mice
compared to their wild-type HO-1+/+ counterpart. In
other words, the MCP-1 expression is extremely sensitive
to fluctuations even under basal nonstressed states in the
absence of HO-1, and the latter seems to exert a potent
restraining effect on the MCP-1 gene regulation. Interest-
ingly, although HO-1 up-regulation is mostly seen as an
adaptive response to various forms of oxidative stresses,
its specific induction does occur in basal nonstressful
stimuli as well [e.g., by the administration of adenosine
3’,5’-cyclic monophosphate (cAMP) or cyclic guanosine
3’,5’-monophosphate (cGMP)]. Such effects are either
protein kinase A (PKA)- or protein kinase G (PKG)-
dependent, as has been elucidated in hepatocyte, smooth
muscle, and endothelial cell culture systems [5]. In any in-
stance, these pharmacologic agents hold a great promise
in the treatment and management of acute renal failure.
Certainly, the use of cAMP or cGMP with the premise
to boost the induction of HO-1 in order to ameliorate
the renal ischemic or toxic injury would be an important
subject matter of future investigations.
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